Allogene’s Cema-Cel Shows Early Promise in Lymphoma Trial, Extends Cash Runway
Event summary
- 58.3% of patients in the Cema-Cel arm achieved MRD clearance vs. 16.7% in the observation arm in the ALPHA3 trial.
- No serious adverse events or hospitalizations reported for Cema-Cel, enabling outpatient management.
- One-third of screening and infusions occurred at community cancer centers, expanding access.
- Completed $200.4 million public offering in April 2026, extending cash runway into Q1 2029.
The big picture
Allogene’s interim results for Cema-Cel highlight the potential of allogeneic CAR T therapy to expand access to earlier-stage lymphoma patients, particularly in community settings. The favorable safety profile and strong MRD clearance data position the company to challenge the constraints of autologous CAR T therapies. With a robust cash position, Allogene is well-funded to pursue its clinical milestones, but execution risks remain as it scales its trials globally.
What we're watching
- Trial Execution
- Whether the ALPHA3 trial can maintain its favorable safety and efficacy profile as it scales globally.
- Autoimmune Pipeline
- The pace at which ALLO-329 progresses through dose escalation and shows clinical activity in autoimmune diseases.
- Financial Discipline
- How Allogene balances increased operating expenses with its extended cash runway.
Related topics